[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intellectual-disability-mild\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intellectual-disability-mild":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100569242","evaluation-of-co-op-for-adolescents-with-mild-intellectual-disability-100569242",false,"NCT06691698","Evaluation of CO-OP for Adolescents With Mild Intellectual Disability","Evaluation of The Cognitive Orientation to Daily Occupational Performance (CO-OP) Approach for Adolescents With Mild Intellectual Disability","CO-OPIF","Study I-II\n\nInclusion criteria\n\n* 13-17 years\n* Diagnosed mild intellectual disability\n* Motivation to reach self-selected goals\n* Ability to identify those goals\n* Possibility to meet once a week for ten weeks\n* Access to a parent or significant other for support during intervention\n\nExclusion criteria:\n\n* Movement related diagnosis (i.e. cerebral palsy or neuro muscular diseases)\n* Diagnosed attention deficit hyperactivity disorder\u002Fattention deficit disorder (ADHD\u002FADD) or autism spectrum disorder\n* Progressive diagnoses\n* Need for language interpreting\n* Need for alternative and augmentative communication (i.e. pictures or signs).\n\nStudy III\n\nInclusion criteria:\n\n* 13-17 years\n* Diagnosed mild intellectual disability\n* Completed CO-OP intervention or at lest half way trough the intervention\n* Opportunity to meet physically for an interview with in a month post and 6 months post intervention.\n* CO-OP intervention done with high fidelity to CO-OP format with a CO-OP therapist that has written field notes, preferrably recruited from study I-II.\n\nExclusion criteria:\n\n* Movement related diagnosis (i.e. cerebral palsy or neuro muscular diseases)\n* Diagnosed attention deficit hyperactivity disorder\u002Fattention deficit disorder (ADHD\u002FADD) or autism spectrum disorder\n* Progressive diagnoses\n* Need for language interpreting\n* Need for alternative and augmentative communication (i.e. pictures or signs).\n\nStudy IV\n\nInclusion criteria:\n\n* Parents with legal guardianship that lives full- or part time with an adolescent reaching the inclusion criteria for study I who has completed CO-OP within or out of the project\n* Opportunity to meet physically for an interview with in a month post and 6 months post the adolescent's completed, or at least half way through, CO-OP intervention.\n\nExclusion criteria:\n\n* Need for language interpreting\n* Need for alternative and augmentative communication (i.e. pictures or signs)\n* Irregular and brief living with the adolescent comparable to less than half-time and therefore does not observe the adolescent's occupational performance enough to answer the interview questions.","ALL","13 Years","17 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Intellectual disability (ID) affects a person throughout life and includes difficulties to manage what is expected in everyday life based on age. One difficulty is to create strategies for and solve problems related to everyday occupations. Treatment options with good evidence to enhance occupational performance for persons with ID are limited. The Cognitive Orientation to Daily Occupational Performance (CO-OP) is an approach with good evidence within other diagnostic groups, i.e. adolescents with cerebral palsy. CO-OP has a unique person-centered approach where the person chooses his\u002Fher own goals and creates his\u002Fher own strategies to reach them. Initial research shows potential for CO-OP with adolescents with ID, although due to scientific flaws there is still a lack of evidence regarding feasibility and effectiveness for adolescents with ID. Based on the results with other diagnostic groups and clinical knowledge and experience, CO-OP can be assumed to be feasible and effective for adolescents with ID and to have a long term effect transferred to everyday life in a way other treatment options do not.\n\nThe aim of the project is to describe and evaluate CO-OP for adolescents with mild ID. Participants will be adolescents aged 13-17 and their parents. The project is designed as a feasibility study with two qualitative, one quantitative and one mixed method data collection. The quantitative data will be ordinal and nominal data from observational and self-assessment assessments. The mixed methods include comparison between filmed sessions and the CO-OP manual, use of field notes to analyse fidelity and needs for adaptations, and comparison between the CO-OP manual and policy documents. The qualitative outcome will be experiences by the adolescents and perceptions of CO-OP by parents.",[28],"Intellectual Disability, Mild",[30,31,32,33,34,35,36,37],"adolescents","executive function","metacognition","mild intellectual disability","occupational therapy","occupational performance","person-centered intervention","self-efficacy","RECRUITING","2025-08-22",{"date":41,"type":42},"2025-08-29","ACTUAL",{"date":44,"type":42},"2025-01-16",{"date":46,"type":22},"2027-03",{"name":48,"class":49},"Örebro University, Sweden","OTHER",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":5},"100600081","pgx-medication-safety-reviews-of-persons-with-idd-100600081","NCT07092852","PGx Medication Safety Reviews of Persons With IDD","Pharmacogenomic-Based Medication Safety Reviews of Persons With Intellectual and Developmental Disabilities","Inclusion Criteria:\n\n* Beneficiary with IDD\n* Reside in a CP Unlimited facility, NY state\n* At least 21 years of age\n\nExclusion Criteria:\n\n* Pregnant\n* Medical or physical abnormality that prevents cheek swab collection","21 Years",{"count":59,"type":22},700,"OBSERVATIONAL","The purpose of this study is to assess the feasibility of a comprehensive medication review and PGx initiative as part of the care process for individuals in the care of CP Unlimited. This initiative may help improve management of medications and overall health and well-being for participating individuals. Please note that in the context of the research being conducted, all information will remain confidential and deidentified for analyses.\n\nUnder the proposed study protocol, CP Unlimited, in partnership with pharmacists at GalenusRx, will implement and assess a comprehensive medication safety and PGx initiative. Almost three quarters of all clinical trials have eligibility criteria resulting in the exclusion of adults with IDD. This study will help address ongoing health practice disparity. As indicated above, the investigators are requesting the authorization of the guardian or representative, on behalf of the participant under their supervision, to enroll this individual in the proposed study because she\u002Fhe is currently prescribed medications or may eventually receive prescribed or over-the-counter medications. Hereinafter, the denomination \"he\u002Fshe, him\u002Fher, his\u002Fher or them\u002Ftheir\" will be used to refer to the individual with IDD.\n\nThe response to medication can be affected by variations in our genes and by other medications and various disease conditions. Information contained in our genes can vary from one patient to another patient and this can explain why we all can respond differently to medications. Genetic testing and a review of his\u002Fher medications can help to determine if the medication will work for him\u002Fher. PGx is how his\u002Fher genes affect the way he\u002Fshe responds to specific drugs. PGx can tell if he\u002Fshe is more or less likely to feel bad reactions to a drug, or if a drug is likely to benefit him\u002Fher and be safe for him\u002Fher to take. Knowing his\u002Fher genetic information and all medicines that he\u002Fshe is taking can help his\u002Fher pharmacist and his\u002Fher doctor find the combination of medicines that will work the best for him\u002Fher, now and in the future.",[28,63,64],"Intellectual Disability, Mild to Moderate","Developmental Disability",[66,67,68,69],"Intellectual disabilities","Developmental disabilities","IDD","pharmacogenomics","NOT_YET_RECRUITING","2025-07-21",{"date":73,"type":42},"2025-07-30",{"date":75,"type":22},"2025-08-01",{"date":77,"type":22},"2028-01-31",{"name":79,"class":80},"GalenusRx, Inc.","INDUSTRY"]